Last reviewed · How we verify

Intravitreal injection of KH902

Chengdu Kanghong Biotech Co., Ltd. · Phase 2 active Biologic

Intravitreal injection of KH902 is a VEGF inhibitor (recombinant fusion protein) Biologic drug developed by Chengdu Kanghong Biotech Co., Ltd.. It is currently in Phase 2 development for Wet age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.

KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.

KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye. Used for Wet age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.

At a glance

Generic nameIntravitreal injection of KH902
SponsorChengdu Kanghong Biotech Co., Ltd.
Drug classVEGF inhibitor (recombinant fusion protein)
TargetVEGF-A, VEGF-B
ModalityBiologic
Therapeutic areaOphthalmology
PhasePhase 2

Mechanism of action

KH902 functions as a VEGF trap, binding and neutralizing VEGF-A and VEGF-B to prevent their interaction with VEGF receptors on endothelial cells. By blocking VEGF signaling, it reduces pathological neovascularization and vascular leakage associated with retinal diseases. The intravitreal injection route delivers the drug directly to the posterior segment of the eye for local therapeutic effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intravitreal injection of KH902

What is Intravitreal injection of KH902?

Intravitreal injection of KH902 is a VEGF inhibitor (recombinant fusion protein) drug developed by Chengdu Kanghong Biotech Co., Ltd., indicated for Wet age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.

How does Intravitreal injection of KH902 work?

KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.

What is Intravitreal injection of KH902 used for?

Intravitreal injection of KH902 is indicated for Wet age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.

Who makes Intravitreal injection of KH902?

Intravitreal injection of KH902 is developed by Chengdu Kanghong Biotech Co., Ltd. (see full Chengdu Kanghong Biotech Co., Ltd. pipeline at /company/chengdu-kanghong-biotech-co-ltd).

What drug class is Intravitreal injection of KH902 in?

Intravitreal injection of KH902 belongs to the VEGF inhibitor (recombinant fusion protein) class. See all VEGF inhibitor (recombinant fusion protein) drugs at /class/vegf-inhibitor-recombinant-fusion-protein.

What development phase is Intravitreal injection of KH902 in?

Intravitreal injection of KH902 is in Phase 2.

What are the side effects of Intravitreal injection of KH902?

Common side effects of Intravitreal injection of KH902 include Conjunctival hemorrhage, Eye pain, Floaters, Intraocular pressure elevation, Endophthalmitis.

What does Intravitreal injection of KH902 target?

Intravitreal injection of KH902 targets VEGF-A, VEGF-B and is a VEGF inhibitor (recombinant fusion protein).

Related